According to DelveInsight, the Irritable Bowel Syndrome (IBS) pipeline comprises 15+ key companies actively developing 20+ treatment therapies for the condition.
Irritable Bowel Syndrome Overview:
Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits, which can manifest as diarrhea, constipation, or a mix of both. The underlying cause remains uncertain but is believed to stem from a combination of abnormal gut motility, visceral hypersensitivity, gut–brain axis dysfunction, and microbiome imbalances. Common triggers include specific foods, stress, and hormonal changes. While there is no definitive cure, symptom management involves dietary adjustments, pharmacological therapies, and lifestyle modifications.
Clinically, IBS presents with recurrent abdominal pain associated with bloating and stool irregularities. Patients may report excessive gas, mucus in stools, and a sensation of incomplete bowel emptying. The severity and frequency of symptoms vary, often fluctuating in response to stress or dietary factors.
Diagnosis primarily relies on clinical criteria, as there are no specific diagnostic tests for IBS. The Rome IV criteria are commonly used, requiring abdominal pain at least one day per week over the past three months, linked to changes in bowel movement frequency, stool form, or pain related to defecation. To rule out other gastrointestinal disorders—such as celiac disease or inflammatory bowel disease (IBD)—clinicians may employ blood tests, stool studies, or colonoscopy.
Request for a detailed insights report on Irritable Bowel Syndrome pipeline insights
DelveInsight’s “Irritable Bowel Syndrome Pipeline Insight 2025” report offers an in-depth evaluation of the ongoing clinical research and future growth opportunities within the Irritable Bowel Syndrome (IBS) therapeutics market.
Key Takeaways from the Irritable Bowel Syndrome Pipeline Report
-
DelveInsight’s Irritable Bowel Syndrome pipeline report highlights a dynamic landscape with over 15 active companies developing more than 20 therapeutic candidates for IBS management.
-
In January 2025, the FDA granted tentative approval to Amneal Pharmaceuticals’ generic rifaximin 550 mg for diarrhea-predominant IBS (IBS-D), with final approval pending resolution of ongoing patent litigation with Bausch Health.
-
Leading companies such as Tryp Therapeutics, CinRx Pharma, Otsuka Pharmaceutical, RaQualia Pharma, Biomica, and Octavian Therapeutics are advancing innovative treatment options to enhance the IBS therapeutic space.
-
Notable pipeline candidates in various stages of development include CIN-103, RQ-00310941, OCT-461201, BMC426, and others.
Irritable Bowel Syndrome Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Irritable Bowel Syndrome Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Irritable Bowel Syndrome treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Irritable Bowel Syndrome market.
Download our free sample page report on Irritable Bowel Syndrome pipeline insights
Irritable Bowel Syndrome Emerging Drugs
CIN-103 – CinRx Pharma
CIN-103 is a novel formulation of phloroglucinol, a non-opioid small molecule already approved in several countries for treating gastrointestinal conditions. Developed for long-term use, CinRx has incorporated both immediate- and delayed-release technologies to create a proprietary pulsatile delivery system that ensures sustained drug exposure with reduced dosing frequency. The therapy targets multiple underlying mechanisms of diarrhea-predominant irritable bowel syndrome (IBS-D), including abnormal motility, secretion, pain, spasms, and inflammation. CIN-103 is currently being evaluated in Phase II clinical trials for IBS.
RQ-00310941 – RaQualia Pharma
RQ-00310941 is an innovative 5-HT2B receptor antagonist developed by RaQualia Pharma for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). The 5-HT2B receptor, a subtype of serotonin receptors, is crucial in controlling gastrointestinal motility. By inhibiting this receptor, the drug is designed to alleviate visceral hypersensitivity and restore normal bowel function in IBS patients. RQ-00310941 is currently undergoing Phase I clinical evaluation for IBS.
Irritable Bowel Syndrome Companies
More than 15 companies are actively engaged in developing treatments for Irritable Bowel Syndrome (IBS). Among these, CinRx Pharma’s drug candidate has reached the most advanced stage of development, currently in Phase II clinical trials.
Request the Sample PDF to Get Detailed Insights About the Irritable Bowel Syndrome Pipeline Reports Offerings
DelveInsight’s report covers around 75+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Irritable Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Irritable Bowel Syndrome Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Irritable Bowel Syndrome Therapies and Key Companies: Irritable Bowel Syndrome Clinical Trials and advancements
Irritable Bowel Syndrome Pipeline Therapeutic Assessment
• Irritable Bowel Syndrome Assessment by Product Type
• Irritable Bowel Syndrome By Stage
• Irritable Bowel Syndrome Assessment by Route of Administration
• Irritable Bowel Syndrome Assessment by Molecule Type
Download Irritable Bowel Syndrome Sample report to know in detail about the Irritable Bowel Syndrome treatment market @ Irritable Bowel Syndrome Therapeutic Assessment
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/